Add to my selection

KYNTHEUM (brodalumab)

Medicine - Posted on Sep 18 2024

Active substance (DCI)

brodalumab

history (4)

7/17/24

KYNTHEUM (brodalumab) - Biothérapies par voie sous cutanée dans les maladies inflammatoires chroniques

Modification des conditions de l'inscription. L'essentiel Avis favorable à la modification des Conditions de Prescription et...

CAV :
54321

icône flèche
7/11/22

KYNTHEUM (brodalumab) - Psoriasis en plaques de l'adulte

Key points Reassessment for the indication of adult plaque psoriasis: Retention of approval for reimbursement for the entire...

CAV :
54321

icône flèche
4/4/18

KYNTHEUM (brodalumab), interleukin inhibitor immunosuppressant

High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by: failure of at least two tre...

CAV :
54321

icône flèche

Technical information

ATC code

L04AC12

Manufacturer

LEO PHARMA

Presentation

KYNTHEUM 210 mg, solution injectable en seringue préremplie (code CIS : 65620419)
2 seringues préremplies en verre de 1,5 ml (CIP : 34009 301 172 8 6)

All our publications

Drug therapy

Pain - Inflammation

Skin and connective tissue diseases

My account

You do not have a saved search

No element in selection

KYNTHEUM (brodalumab)

KYNTHEUM (brodalumab) - Biothérapies par voie sous cutanée dans les maladies inflammatoires chroniques

KYNTHEUM (brodalumab) - Psoriasis en plaques de l'adulte

KYNTHEUM (brodalumab), interleukin inhibitor immunosuppressant

Follow us :